Securities Code: 002399 Securities Abbreviation: Hepalink Announcement No.: 2026-007 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announcement on Application for Credit Line and Provision of Guarantees for 2026 The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and that there are no false or misleading statements or material omissions. Special Notice:
- The total amount of external guarantees for the Company and its consolidated subsidiaries within the next twelve months is expected not to exceed RMB 10,090,000,000, accounting for 83.87% of the Company's net assets as audited for the most recent year. The Company and its consolidated subsidiaries do not provide guarantees for entities outside the consolidated scope.
- The total amount of guarantees for wholly-owned subsidiaries with an asset-liability ratio exceeding 70% within the next twelve months for the Company and its consolidated subsidiaries is expected not to exceed RMB 80,000,000, accounting for 6.65% of the Company's net assets as audited for the most recent year. Investors are kindly requested to pay attention to the guarantee risks. I. Application for Credit Line and Provision of Guarantees for 2026 To meet the business and operational development needs of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") and its wholly-owned subsidiaries, the Company and its wholly-owned subsidiaries, Hepalink (Hong Kong) Co., Ltd. (hereinafter referred to as "Hong Kong Hepalink"), Shenzhen Tiandao Pharmaceutical Co., Ltd. (hereinafter referred to as "Tiandao Pharmaceutical"), Tiandao Pharmaceutical (Hong Kong) Co., Ltd. (hereinafter referred to as "Tiandao Hong Kong"), and SPL Acquisition Corp. (hereinafter referred to as "SPL") plan to apply for comprehensive credit lines (including renewal of expiring credit lines) from various banks and financial institutions in 2026. In addition, the Company and its wholly-owned subsidiaries will provide guarantees to banks and financial institutions for a portion of the aforementioned credit lines. (I) Proposed Credit Line Application As of the end of 2025, the Company and its wholly-owned subsidiaries have obtained credit lines from banks and financial institutions totaling approximately RMB 15,497,861,400, with an actual utilization of approximately RMB 3,113,529,300. The proposed credit line for the Company and its wholly-owned subsidiaries in 2026 (in RMB) is expected to be as follows:
| Applicant | Credit Line Amount (RMB Ten Thousand) | Purpose | Credit Terms | Shareholding Ratio |
|---|---|---|---|---|
| Company | 800,000.00 | Medium and long-term fixed asset loans, medium and long-term working capital loans, short-term working capital loans, trade financing, financing guarantees, procurement of raw materials, daily operational turnover, replacement of other bank loans, export bills, foreign exchange derivatives, etc. | Joint and several liability guarantee from the Company and Tiandao Pharmaceutical | 100% |
| Hong Kong Hepalink | 20,000.00 | Medium and long-term fixed asset loans, medium and long-term working capital loans, short-term working capital loans, trade financing, financing guarantees, procurement of raw materials, daily operational turnover, replacement of other bank loans, export bills, foreign exchange derivatives, etc. | Joint and several liability guarantee from the Company | 100% |
| Tiandao Hong Kong | 80,000.00 | Medium and long-term fixed asset loans, medium and long-term working capital loans, short-term working capital loans, trade financing, financing guarantees, procurement of raw materials, daily operational turnover, replacement of other bank loans, export bills, foreign exchange derivatives, etc. | Joint and several liability guarantee from the Company | 100% |
| SPL | 50,000.00 | Medium and long-term fixed asset loans, medium and long-term working capital loans, short-term working capital loans, trade financing, financing guarantees, procurement of raw materials, daily operational turnover, replacement of other bank loans, export bills, foreign exchange derivatives, etc. | SPL asset mortgage | 100% |
| Tiandao Pharmaceutical | 804,000.00 | Medium and long-term fixed asset loans, medium and long-term working capital loans, short-term working capital loans, trade financing, financing guarantees, procurement of raw materials, daily operational turnover, replacement of other bank loans, export bills, foreign exchange derivatives, etc. | Joint and several liability guarantee from the Company | 100% |
| Tiandao Pharmaceutical | 100,000.00 | Medium and long-term fixed asset loans, medium and long-term working capital loans, short-term working capital loans, trade financing, financing guarantees, procurement of raw materials, daily operational turnover, replacement of other bank loans, export bills, foreign exchange derivatives, etc. | Pure credit | 100% |
| Total | 1,854,000.00 |